

Cytomegalovirus reactivation in non-severe COVID-19: two emblematic cases of oropharyngeal mucositis in immunocompromised patients

R. Astorri², A. Russo^{1,2}, P. Medusa², N. Carro², A. Dell'Aquila², I. Palma², C. Ricozzi², K. Gjeloshi², S. Imbriani², C. Sagnelli^{1,2}, M. Pisaturo ^{1,2}, N. Coppola ^{1,2}

CASES

AGE

RPA

IMMUNOSUPPRESSIVE DRUG

SARS-COV-2 VACCINATION STATUS

PPA

1st POSITIVE SARS-CoV-2 NPS

CMV DNA (WHOLE BLOOD)

SARS-CoV-2 RNA (NPS)

ADDITIONAL INFO

GENERAL CLINICAL PRESENTATION

GENERAL MANAGEMENT

COVID-19 EARLY THERAPIES

DERMATOLOGICAL CLINICAL FEATURES

CMV THERAPY (START

CLINICAL-VIROLOGICAI IMPROVEMENT

Table- Schematic presentation of the cases

48

CCS

3 DOSES, mRNA-b

Chest CT (10/11/2022): diffuse GGOs, wide

2/11/2022

(12/11/2022) : 202 UI/mL (2/12/2022): 1761 UI/mL (30/12/2022): 10507 UI/m

(14/11/2022): CT 20, 21, 20 (2/12/2022): CT 19, 19, 19 (2/1/2023): CT 29, 30, 29

10/11/2022) UATs (Legionella, S.

pneumoniae): negative HSV 1-2 IgM/IgG: negative (12/11/2022) serum BDG: 41.82 pg/m (12/11/2022) serum EBV DNA: negati (12/11/2023) HBV, HCV, HIV screenin

Low-grade fever, dyspnea (on exertion)

Therapy: ATB, CCS, oxygen (27/11/2022) topical nistatin, oral calation to IV fluconazole, 2 days la

CONTRAINDICATED/REJECTED

(1/12/2022): appearance of 2 small t ulcers (~ 7-8mm, painful), upon oral

3/1/2023)

(July, 2023) -

(10/11/2022) - I hospital ad

64

3 DOSES, mRNA-b

due to respiratory failure) concurrent COVID-19 diagnosis; Chest CT: typical, CT severity score 12/ Therapy: CCS, oxygen, antivirals (see b

(20/3/2023) - II hospital admission (due to respiratory failure, P/F nadi 162), Chest CT: typical, CT severity score 20/25, Therapy: CCS, oxygen, early therapies (se below)

28/2/2023

(11/4/2023): 1360 UI/mL (28/4/2023): 170 UI/ml

(11/4/2023): CT 31,31,31 (28/4/2023): CT 31,31,31 (11/5/2023): CT 23, 21, 21

(March 2023) UATs (Legionella and S. pneumoniae): negative (11/4/2023) HBV, HCV, HIV screening, and

negative; m BDG and GM: negative m inflammatory markers: stably neg

Fever, cough, dyspnea (on exertion), epist

Therapy: ATB, CCS, oxyger

(28/2/2023): RDV (5 days)

(20/3/2023) RDV (10 days), TCZ, (21/3/23)

17/4/2023

5-7 days

(28/4/2023) serum protein elect 0.3 g/dL (total p albumin 2.7) (4/5/2023) lymphocytes subtyping: CD4+ 386 cell/uL, CD8 369, CD4/CD8 1.00, (7/4/2023) PLT nadir 100000/µL (basal

(28/2/2023) - I h

therapy, at hom MI (2022), carpa

1. Infectious Disease Unit, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli" - Naples (Italy) 2. Infectious Disease Unit - AOU "Vanvitelli", Naples (Italy)

Background

- This new phase of COVID-19 pandemic is characterized by a more sustainable burden, as it is dominated by less virulent variants interacting with a limitedly susceptible population, due to the presence of a broad specific immunization (either natural or due to large-scale vaccination programmes), in immunocompetent individuals
- In this milder phase, increasing interest is dedicated to the understanding of COVID-19 postacute sequelae and to obtain a clearer view its clinical heterogeneity. In particular, focusing on non-severe COVID-19 may reveal the mechanisms of a subacute clinical progression, and highlight the role of coinfections and reactivations of latent pathogens, particularly highprevalence viruses, such as herpesviruses
- Undoubtedly, immunocompromised subjects represent the main challenge of the current phase, due to a limited response to vaccines, prolonged viral shedding, and reactivation of microorganisms.
- Cytomegalovirus (CMV) is a well-known exacerbating factor of severe COVID-19, particularly of pneumonia, but wide knowledge gaps remain about CMV role in non-severe COVID-19, especially when dermatological clinical features are concerned. As a consequence, specific therapeutic management is not clearly defined.

Cases description and discussion

- The two reported cases (detailed in the Table) presented some important common features. Both were immunosuppressed due to a rheumatological disease (F, 48 years; mixed connective tissue disease with Sjögren syndrome and seronegative arthritis) or, combinedly, rheumatological and oncohaematological disorders (M, 64 years; ankylosing spondylitis and chronic lymphatic leukemia), undergoing anti-CD20 therapy (rituximab).
- The two subjects exhibited a long-term positivity (months) of SARS-CoV-2 nasopharyngeal swabs, with radiological findings of severe persisting lung alterations, but with a largely compensated clinical presentation, due to a slow adaptation. Both developed orolabial painful herpes-like lesions (Figure), in the presence of CMV-DNA on blood samples, documented by PCR. Bioptic sampling of the lesions was rejected by the patients.
- In both cases, the administration of valganciclovir correlated with rapid relief and a regression of the lesions, with a comparable timing of about 5 days;
- Our observations are clearly limited by their "ex adiuvantibus" nature and by the availability of a limited sample. Nevertheless, literature evidence for CMV role in non-severe COVID-19 patients is drastically scarce. Thus, we suggest that a quantity of orolabial ulcers may be due to a low-level replication of CMV, rather than SARS-CoV-2 itself, and it would be ideal to understand the targets of CMV-specific therapies.

Conclusions

- COVID-19 patients with aphtous oral-perioral mucocutaneous lesions and a documented systemic replication of CMV (even low-grade), are likely to benefit from CMV-specific therapies.
- When feasible and accepted, bioptic studies may support the definition of the pathogenetic role of CMV in these patients, to offer therapeutic responses to a likely underestimated and undertreated subgroup of patients with mild CMV manifestations in mild COVID-19.


References

doi:10.7554/eLife.86015

37288151: PMCID: PMC10243944

2

3.



Chen B, Julg B, Mohandas S, Bradfute SB; RECOVER Mechanistic Pathways Task Force. Viral persistence, reactivation, and mechanisms of long COVID. Elife. 2023;12:e86015. Published 2023 May 4

Ura K, Goubaru Y, Motoya M, Ishii H. Coinfection with SARS-CoV-2 and Cytomegalovirus in a Patient with Mild COVID-19. Case Rep Infect Dis. 2023 May 30;2023:6684783. doi: 10.1155/2023/6684783. PMID: